Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess
Open Access
- 9 July 2021
- journal article
- research article
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 23 (2) , 233-250
Abstract
Patients with endogenous or exogenous glucocorticoid (GC) excess exhibit a range of side effects, including an increased risk of infections. Via both mechanism, immune impairments and cardiometabolic concomitant diseases, patients with GC excess could be at increased risk for COVID-19. The impact on incidence and outcome of a SARS-CoV-2 infection in this population are not yet completely clear. This review aims to compile the data available to date and to discuss the existing literature on this topic. Further we highlight potential effects of SARS-CoV-2 on the hypothalamic-pituitary-adrenal axis as well as the influence of endogenous or exogenous GC excess on SARS-CoV-2 mRNA vaccination. There is growing evidence suggesting an increased risk of infection and severe outcome in patients with high-dose GC therapy after contracting SARS-CoV-2. The few data and case reports on patients with endogenous GC excess and SARS-CoV-2 infection point in a similar direction: chronic GC excess seems to be associated with an unfavorable course of COVID-19. Whether this is mainly a primary immune-mediated effect, or also triggered by the many GC-associated comorbidities in this population, is not yet fully understood. Patients with endogenous or exogenous GC excess should be considered as a vulnerable group during the SARS-CoV-2 pandemic. Regardless of the cause, vaccination and consistent surveillance and control of associated comorbidities are recommended.Keywords
Funding Information
- Ludwig-Maximilians-Universität München
This publication has 127 references indexed in Scilit:
- Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysisAnnals of the Rheumatic Diseases, 2012
- A Prospective Study of the Factors Shaping Antibody Responses to the AS03-Adjuvanted Influenza A/H1N1 Vaccine in Cancer OutpatientsThe Oncologist, 2012
- Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseasesArthritis Care & Research, 2011
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insightsMolecular and Cellular Endocrinology, 2011
- Cardiovascular Disease in Cushing’s Syndrome: Heart versus VasculatureNeuroendocrinology, 2010
- Epidemiology of Cushing’s SyndromeNeuroendocrinology, 2010
- Corticothérapie systémique et risque infectieuxLa Revue de Médecine Interne, 2007
- Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinionBritish Journal of Dermatology, 2007
- Effects of long-term low-dose corticosteroid therapy on humoral immunityAnnals of Allergy, Asthma & Immunology, 2006
- Molecular mimicry of ACTH in SARS – implications for corticosteroid treatment and prophylaxisMedical Hypotheses, 2004